FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969861750> ?p ?o ?g. }

• W2969861750 endingPage "113" @default.
• W2969861750 startingPage "91" @default.
• W2969861750 abstract "Background: Approximately 75% of all deaths in people with schizophrenia are caused by physical illness with cardiovascular disease [CVD] being the commonest cause of death. Factors predisposing people with schizophrenia to CVD include antipsychotic medication. Aim of Work: The aim of this study was to detect metabolic syndrome and its components in de novo paranoid schizophrenics on olanzapine therapy and the metabolic benefits of addition of aripeprazole, clinically and experimentally. Methodology: 1) Clinical study: 200 Outpatients suffered from de novo paranoid schizophrenia according to 10th International Classification of Psychiatric Disorders, Research Criteria [ICD10 RC] were included in the study. None of them had any component of metabolic syndrome. They were maintained on olanzapine [10 - 20 mg]. Patients were assessed clinically, psychometrically using Scale for the Assessment of Negative [SANS] and Positive [SAPS] Symptoms and metabolically at base line and after 6 months. Patients who had metabolic syndrome after 6 month of starting olanzapine therapy, were randomly divided into two groups according to added regime to maintained olanzapine: Group 1: olanzapine [10 mg/day] + placebo [empty hard gelatin capsule]. Group II: olanzapine [10 mg/day] + aripeprazole [10 mg/day]. 2) Experimental study: 40 male albino rats were randomly equally divided into 4 groups: Group 1 [control group]: received a standard diet, Group II [olanzapine treated]: received olanzapine at a dose of 0.5 mg/kg/day, Group III [aripiprazole treatd]: received aripiprazole at a dose of 2 mg/kg/day, Group IV [combined olanzapine and aripiprazole treated]: received olanzapine at a dose of 0.5 mg/kg/day combined with aripiprazole at a dose of 2 mg/kg/day orally. The duration of the study was 16 weeks. All treated rat groups were assessed for metabolic parameters, liver enzymes and histopathology. Results: Clinically, after the 6 months of olanzapine treatment [mean dose 12.75 mg], there was significant increase [p < 0.001] in weight, body mass index, triglyceride, total cholesterol, and fasting blood glucose level compared to base line level of these parameters (Table 1). 32 patients [16%] suffered from metabolic syndrome after 6 months of olanzapine therapy. After 3 months of aripeprazole, [10 mg/day], addition to maintained olanzapine therapy to patients suffered from metabolic syndrome, there was significant [p < 0.001] improvement in tested parameters (Table 2). Experimentally, the rats in group II [olanzapine treated rats] had significantly higher body weight [p = 0.002], liver weight [p < 0.001], metabolic parameters [p < 0.001] and liver enzymes [p < 0.001] than controls. Group 1v [combined olanzapine and aripeprazole treated rats] had significant decrease in metabolic parameters and liver enzymes in comparison to olanzapine treated rats (Table 3). Histopathologically, liver fat cells were significantly [p < 0.001] present in the olanzapine-only [8 rats] treatment group compared to group 1v [3 rats] and group 11 [zero]. Liver fat cells were higher in number and larger in size in group 1 compared to group 1v and group 1. Conclusion and Recommendation: Olanzapine treatment was found to be associated with risk factors of metabolic syndrome clinically and experimentally and its hepatic manifestation of non-alcoholic fatty liver disease in wister rats. Improvements were observed clinically and experimentally in metabolic measures, liver enzymes and liver histopathology by addition of aripeprazole. Patients on olanzapine therapy must be followed regularly regarding metabolic parameters, hepatic, cardiac and cerebrovascular morbidity, with urgent interference with early manifestations. It is recommended to check liver enzymes regularly for those patients kept on atypical antipsychotic drug [olanzapine]." @default.
• W2969861750 created "2019-08-29" @default.
• W2969861750 creator A5012391891 @default.
• W2969861750 creator A5090589243 @default.
• W2969861750 date "2019-01-01" @default.
• W2969861750 modified "2023-10-01" @default.
• W2969861750 title "Potential Toxic Effects of Olanzapine on Metabolic Parameters in <i>de Novo</i> Paranoid Schizophrenic Patients. The Role of Adjunctive Aripeprazole: Clinical and Experimental Study" @default.
• W2969861750 cites W1584182128 @default.
• W2969861750 cites W166500168 @default.
• W2969861750 cites W1970840734 @default.
• W2969861750 cites W1972902245 @default.
• W2969861750 cites W1985485609 @default.
• W2969861750 cites W1986800512 @default.
• W2969861750 cites W1989488925 @default.
• W2969861750 cites W1989974319 @default.
• W2969861750 cites W1991630431 @default.
• W2969861750 cites W1993446055 @default.
• W2969861750 cites W1995631390 @default.
• W2969861750 cites W1996322694 @default.
• W2969861750 cites W2000265560 @default.
• W2969861750 cites W2010135111 @default.
• W2969861750 cites W2023159509 @default.
• W2969861750 cites W2025610697 @default.
• W2969861750 cites W2026564565 @default.
• W2969861750 cites W2028060030 @default.
• W2969861750 cites W2030978712 @default.
• W2969861750 cites W2031176605 @default.
• W2969861750 cites W2031894898 @default.
• W2969861750 cites W2038256637 @default.
• W2969861750 cites W2043075431 @default.
• W2969861750 cites W2047066979 @default.
• W2969861750 cites W2047372772 @default.
• W2969861750 cites W2048842094 @default.
• W2969861750 cites W2048851078 @default.
• W2969861750 cites W2051108113 @default.
• W2969861750 cites W2053508950 @default.
• W2969861750 cites W2055620491 @default.
• W2969861750 cites W2056672347 @default.
• W2969861750 cites W2063231575 @default.
• W2969861750 cites W2064125890 @default.
• W2969861750 cites W2069713338 @default.
• W2969861750 cites W2077808864 @default.
• W2969861750 cites W2080407540 @default.
• W2969861750 cites W2086748382 @default.
• W2969861750 cites W2087829753 @default.
• W2969861750 cites W2089671853 @default.
• W2969861750 cites W2090191759 @default.
• W2969861750 cites W2091712663 @default.
• W2969861750 cites W2093088436 @default.
• W2969861750 cites W2097572674 @default.
• W2969861750 cites W2100358362 @default.
• W2969861750 cites W2103714496 @default.
• W2969861750 cites W2106966901 @default.
• W2969861750 cites W2108988641 @default.
• W2969861750 cites W2111105929 @default.
• W2969861750 cites W2116251861 @default.
• W2969861750 cites W2116643778 @default.
• W2969861750 cites W2117209734 @default.
• W2969861750 cites W2117234502 @default.
• W2969861750 cites W2117811890 @default.
• W2969861750 cites W2119971225 @default.
• W2969861750 cites W2121634450 @default.
• W2969861750 cites W2123521914 @default.
• W2969861750 cites W2123581040 @default.
• W2969861750 cites W2125393540 @default.
• W2969861750 cites W2126094071 @default.
• W2969861750 cites W2129448542 @default.
• W2969861750 cites W2130717716 @default.
• W2969861750 cites W2132164701 @default.
• W2969861750 cites W2134164029 @default.
• W2969861750 cites W2138691846 @default.
• W2969861750 cites W2143104968 @default.
• W2969861750 cites W2149288810 @default.
• W2969861750 cites W2150458484 @default.
• W2969861750 cites W2155500949 @default.
• W2969861750 cites W2159039084 @default.
• W2969861750 cites W2167532647 @default.
• W2969861750 cites W2168121374 @default.
• W2969861750 cites W2169388316 @default.
• W2969861750 cites W2170663130 @default.
• W2969861750 cites W2264982161 @default.
• W2969861750 cites W2317690366 @default.
• W2969861750 cites W2322554067 @default.
• W2969861750 cites W2527328081 @default.
• W2969861750 cites W2554239809 @default.
• W2969861750 cites W2615637571 @default.
• W2969861750 cites W4232541108 @default.
• W2969861750 cites W4297040264 @default.
• W2969861750 cites W605159704 @default.
• W2969861750 cites W74340591 @default.
• W2969861750 doi "https://doi.org/10.4236/odem.2019.73008" @default.
• W2969861750 hasPublicationYear "2019" @default.
• W2969861750 type Work @default.
• W2969861750 sameAs 2969861750 @default.
• W2969861750 citedByCount "0" @default.
• W2969861750 crossrefType "journal-article" @default.
• W2969861750 hasAuthorship W2969861750A5012391891 @default.
• W2969861750 hasAuthorship W2969861750A5090589243 @default.

• next